In 2009, GRAPPA published their first evidence-based recommendations for the treatment of
psoriasis and psoriatic arthritis (PsA). Since then, new information has been published and …

Background Patients who have had inadequate response to tumour necrosis factor inhibitors
have fewer treatment options and are generally more treatment refractory to subsequent …

Objective To develop new composite disease activity indices for psoriatic arthritis (PsA).
Methods Data from routine clinic visits at multiple centres were collected in a systematic manner. …

Objective To investigate whether rituximab, an anti–B cell therapy, improves symptoms of
fatigue and oral dryness in patients with primary Sjögren's syndrome (SS). Methods We …

The aim of this study is to assess the gender differences in spondyloarthritides (SpAs) in
terms of disease onset, clinical presentation, and the Bath Ankylosing Spondylitis Disease …

Objectives To compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS)
in primary Sjögren’s syndrome (PSS) in a multicentre, multiobserver phase III trial …

Objective Rheumatoid arthritis ( RA ) is associated with increased cardiovascular event ( CVE
) risk. The impact of statins in RA is not established. We assessed whether atorvastatin is …

Objective To establish the predictive validity of the Assessment of SpondyloArthritis international
Society (ASAS) spondyloarthritis (SpA) classification criteria. Methods 22 centres (N=…

There are a wide variety of medications available to treat patients with rheumatoid arthritis,
many of which are considered unsafe during pregnancy. It is important to tailor a treatment …

Objective Psoriatic arthritis (PsA) has been defined as a systemic, chronic, inflammatory
arthritis, usually seronegative for rheumatoid factor (RF), associated with cutaneous psoriasis. …